DSIP (5 mg) — Image courtesy of White Market Peptides

At a Glance

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nine-amino-acid neuropeptide studied for its ability to promote deep delta-wave sleep and modulate the HPA axis. Published human research used intravenous administration; community researchers typically use subcutaneous injection at lower doses extrapolated from animal data.[1]

Reconstitute: Add 3.0 mL bacteriostatic water → 1.67 mg/mL (1,667 mcg/mL) concentration.
Standard dose: 250–300 mcg before sleep subcutaneous injection, 30–60 minutes prior to sleep, titrated up over the first weeks.
Easy measuring: At 1.67 mg/mL on a U-100 syringe, 1 unit = 0.01 mL ≈ 16.7 mcg. A 250 mcg dose = 15 units / 0.15 mL.
Doses per vial: ~20 doses at 250 mcg (≈17 at 300 mcg); use within 4 weeks of reconstitution.
Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.

Overview

Goal: Promote deep delta-wave sleep via neuropeptide modulation of sleep architecture and HPA axis.[1]
Schedule: Subcutaneous injection once daily in the evening, 30–60 minutes before sleep, over a 4–8 week cycle (optional extension to 12 weeks with periodic breaks).
Dose: 100–300 mcg per injection (6–18 units / 0.06–0.18 mL), titrated; standard 250–300 mcg.
Reconstitution: 3.0 mL BAC water per 5 mg vial → 1.67 mg/mL.
Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

What You’ll Need

Plan based on an 8-week once-daily course titrated from 100 mcg up to 250–300 mcg (56 injections, approx. 12,800 mcg total).

DSIP Vials (5 mg each): 12,800 mcg ÷ 5,000 mcg per vial → 3 vials (~20 doses per vial at 250 mcg).
Insulin Syringes (U-100, 1 mL): 1 per injection → 56 syringes for the course.
Bacteriostatic Water (10 mL bottles): 3.0 mL per vial × 3 vials → 1 × 10 mL bottle.
Alcohol Swabs: 2 per injection → 112 swabs for the course.

How to Reconstitute

Allow frozen vial to reach room temperature (10–15 minutes).
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the inner vial wall; do not inject directly onto the lyophilised cake.
Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
Label with reconstitution date; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Dosing Schedule

Phase	Dose	Units (U-100)	Volume	Timing
Week 1	100 mcg	6 units	0.06 mL	30–60 min before sleep
Week 2	150 mcg	9 units	0.09 mL	30–60 min before sleep
Week 3	200 mcg	12 units	0.12 mL	30–60 min before sleep
Weeks 4–8	250–300 mcg	15–18 units	0.15–0.18 mL	30–60 min before sleep

Reconstitute each 5 mg vial with 3.0 mL bacteriostatic water for a concentration of 1.67 mg/mL (1 unit on a U-100 syringe ≈ 16.7 mcg). Administer subcutaneously once daily in the evening, 30–60 minutes before intended sleep time. Start low and step the dose up weekly: DSIP shows a U-shaped dose-response, so titrate gradually and hold at the lowest dose that produces a consistent effect.[3] DSIP is not intended for daytime use.[1]

Protocol Details

Week 1: 100 mcg (6 units / 0.06 mL) subcutaneous, once daily, 30–60 min before sleep.[2]
Week 2: 150 mcg (9 units / 0.09 mL) subcutaneous, once daily, 30–60 min before sleep.
Week 3: 200 mcg (12 units / 0.12 mL) subcutaneous, once daily, 30–60 min before sleep.
Weeks 4–8 (standard): 250–300 mcg (15–18 units / 0.15–0.18 mL) subcutaneous, once daily, 30–60 min before sleep.
Advanced (optional): Some researchers extend to 350–500 mcg (21–30 units / 0.21–0.30 mL) once daily from week 5+; note that formal human studies used ≤ ~300 mcg equivalents, so this tier exceeds the documented range.
Frequency: Once daily, in the evening 30–60 minutes before sleep.
Cycle: 4–8 weeks; optional extension to 12 weeks with periodic breaks.
Injection site: Abdomen, thigh, or upper arm. Rotate sites between injections.
Note: An initial mild arousal effect may occur in the first hour; sleep-promoting effects typically emerge in the second hour.[2]

Storage

Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
Appearance: Clear, colourless solution. Discard if cloudy, discoloured, or particulate.

How DSIP Works

DSIP is a nine-amino-acid neuropeptide (WAGGDASGE; MW 849 Da) first isolated from the cerebral venous blood of sleeping rabbits by Schoenenberger & Monnier at the University of Basel in 1977.[1] The most distinctive feature of DSIP — and its primary scientific puzzle — is that its receptor has never been identified despite nearly five decades of research.

What is established: DSIP crosses the blood-brain barrier via both passive diffusion and a saturable transport system. It modulates the hypothalamic-pituitary-adrenal (HPA) axis, correlating with cortisol levels. It interacts with the pineal gland through N-acetyltransferase modulation, influencing melatonin synthesis. Its antinociceptive effects in animals are blocked by the opioid antagonist naloxone, suggesting functional interaction with opioid receptors.[4] The net result of these interactions — in the correct dose and timing window — is an enhancement of delta-wave (slow-wave) EEG activity and deeper sleep architecture.

Good to Know

Published human research used intravenous administration at 25 nmol/kg (≈1.5 mg IV for 70 kg). Community subcutaneous dosing at 100–300 mcg is extrapolated from animal research — no human pharmacokinetic data for SC DSIP exists.
DSIP shows a U-shaped dose-response curve in animal models — both sub-optimal and supra-optimal doses may produce diminished or reversed effects. Start at 100 mcg and step up weekly, holding at the lowest dose that produces a consistent effect.[3]
Cumulative benefit was observed across multiple administrations in human IV studies; results on a single night may be modest.
Do not use concurrently with opioid medications — DSIP has demonstrated opioid receptor activity and additive CNS/respiratory depression is theoretically possible.
Athletes subject to anti-doping rules should seek written confirmation from their Anti-Doping Organization before use; WADA Section S2 catch-all clauses may apply.
Sleep (human IV data): Weak but statistically significant improvements in sleep efficiency and onset latency in the only double-blind study (Bes et al. 1992, N=16); no subjective improvement was found.[2] Earlier open studies were more positive but less controlled.
Withdrawal (uncontrolled human data): 87–97% of 107 inpatients showed marked improvement in alcohol or opiate withdrawal symptoms (Dick et al. 1984); no placebo group was included.[5]
Pain (animal data): Supraspinal opioid-mediated analgesia confirmed in mice; no human analgesic trials exist.[4]
Neuroprotection (animal data): Intranasal DSIP accelerated motor recovery post-stroke in rats; Deltaran combination achieved 100% ischemia survival vs. 62% in controls.
First-hour arousal: An initial mildly arousing effect in the first hour post-injection is documented in human studies; do not expect immediate sedation.
No daytime sedation reported in any published human study.
For background on DSIP's mechanism, evidence, and safety profile, see What Is DSIP?.

Tips for Best Results

Administer 30–60 minutes before the intended sleep time to align with the delayed onset of sleep-promoting effects.
Minimize blue-light exposure and screen use in the 30–60 minutes post-injection to support the transition to sleep.
Maintain a consistent sleep schedule — DSIP modulates natural sleep architecture and works best when circadian rhythms are regular.
Start at 100 mcg in week 1 and step up weekly (150 mcg, then 200 mcg) before settling at 250–300 mcg; the U-shaped dose-response means more is not always better.
Adequate dietary magnesium and consistent wind-down routines complement sleep peptide research protocols.

Injection Tips

Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.

DSIP (5 mg)